
01/12/2023
Immunotherapy combinations based on nivolumab entail lower costs for grade 3/4 adverse events than those using pembrolizumab, a finding that could inform treatment decisions.
Over 100 years experience treating the most difficult cancers.
Albuquerque, NM
Monday | 8am - 5pm |
Tuesday | 8am - 5pm |
Wednesday | 8am - 5pm |
Thursday | 8am - 5pm |
Friday | 8am - 5pm |
Be the first to know and let us send you an email when New Mexico Oncology Associates posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Send a message to New Mexico Oncology Associates: